Calidi Biotherapeutics Taps SIGA Technologies to Boost Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics (NYSE:CLDI) has entered into a collaboration with SIGA Technologies (NASDAQ:SIGA) to develop Calidi's RTNova virotherapy platform for lung cancer and metastatic solid tumors. The collaboration will leverage SIGA's TPOXX antiviral agent to manage RTNova's spread in vivo.
June 10, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics has partnered with SIGA Technologies to develop its RTNova virotherapy platform, focusing initially on lung cancer and metastatic solid tumors. This collaboration could accelerate the development and potential market entry of RTNova.
The partnership with SIGA Technologies provides Calidi with the necessary support to develop its RTNova virotherapy platform, potentially accelerating its development and market entry. This is significant for investors as it could lead to future revenue growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
SIGA Technologies has entered into a collaboration with Calidi Biotherapeutics to support the development of Calidi's RTNova virotherapy platform. SIGA's TPOXX antiviral agent will be tested as a safety switch for RTNova, potentially expanding SIGA's market applications.
The collaboration with Calidi Biotherapeutics allows SIGA to explore new applications for its TPOXX antiviral agent, potentially expanding its market reach and revenue streams. This is positive news for SIGA's growth prospects.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80